Zybrestat (fosbretabulin tromethamine; Mateon Therapeutics) is a water-soluble prodrug of cis-combretastatin A4, originally isolated from the African bush willow (Combretum caffrum). Zybrestat acts as a vascular disrupting agent that rapidly depolymerizes tubulin. By disrupting tubulin formation, Zybrestat inhibits the formation of endothelial cells surrounding tumor vasculature, limiting blood supply to the tumor. Eventually, this leads to ischemia and necrosis of the cancerous tissue.
Zybrestat is being developed for relapsed platinum-resistant ovarian cancer patients in combination with chemotherapy and an already approved drug, Avastin (bevacizumab; Genentech/Roche/Chugai). The platinum-resistant setting remains an area of unmet need, but use as part of a combination regimen could cause excessive toxicity in patients that are typically treated with monotherapies. Mature data from the ongoing Phase II/III FOCUS trial are needed to better determine the drug’s efficacy and tolerability in relapsed platinum-resistant patients.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Zybrestat : Ovarian cancer
LIST OF FIGURES
8 Figure 1: Zybrestat for ovarian cancer – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment of Zybrestat for ovarian cancer
10 Figure 3: Datamonitor Healthcare’s drug assessment of Zybrestat for ovarian cancer
LIST OF TABLES
5 Table 1: Zybrestat drug profile
6 Table 2: Zybrestat Phase II/III data in ovarian cancer
7 Table 3: Phase II data for Zybrestat in ovarian cancer
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.